Tonix Pharmaceuticals (TNXP) announced the in-licensing of worldwide rights to TNX-4800, which is a long-acting human monoclonal antibody that targets the outer surface protein A of Borrelia burgdorferi, the causative agent of Lyme disease in humans. TNX-4800 is being developed for annual seasonal use, as one subcutaneous dose administered in the Spring to protect against Lyme disease through Fall, or the entire tick season in the U.S. TNX-4800 was developed by researchers at UMass Chan Medical School, which is licensing the technology to Tonix. There are currently no FDA-approved vaccines or prophylactics to protect against Lyme Disease.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals presents clinical data on Tonmya at PAINWEEK
- Three new option listings and one option delisting on September 4th
- Tonix Pharma Faces Setback Despite FDA Approval
- Atlassian, CoreWeave, Duke Energy, Tonix Pharma, Dexcom: Insider Moves Unveiled!
- Tonix Pharmaceuticals Reports Q2 2025 Financial Results